fulvestrant has been researched along with Diarrhea in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armgardt, E; Miller, J; Svoboda, A | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Cai, Z; Enatsu, S; Ishiguro, H; Omori, Y | 1 |
| André, F; Campone, M; Ciruelos, E; Conte, P; Hirawat, S; Inoue, K; Iwata, H; Juric, D; Kaufman, B; Loibl, S; Longin, AS; Lu, YS; Mayer, IA; Mills, D; Pápai, Z; Rubovszky, G; Rugo, HS; Takahashi, M; Wilke, C; Yamashita, T | 1 |
2 trial(s) available for fulvestrant and Diarrhea
| Article | Year |
|---|---|
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
Alpelisib for
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Diarrhea; Female; Fulvestrant; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Thiazoles | 2019 |
2 other study(ies) available for fulvestrant and Diarrhea
| Article | Year |
|---|---|
The efficacy and safety of alpelisib in breast cancer: A real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Retrospective Studies | 2022 |
Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Fulvestrant; Humans; Japan; Middle Aged; Patient Preference; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Socioeconomic Factors; Surveys and Questionnaires | 2019 |